Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...
LUND, SE / ACCESS Newswire / January 22, 2025 / Alligator Bioscience (STO:ATORX)Sharpened focus on mitazalimab and cost-reduction program to maximize long-term value creationAnnouncement of rights iss ...
A clinical trial demonstrates the effectiveness of telephone-delivered acceptance and commitment therapy (ACT) in reducing fatigue's interference with functioning and improving the quality of life for ...